The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
Feature|Videos|March 31, 2026
Veridix Document Authoring: Your AI Co-Author for Clinical Documents
Author(s)Nageswara Kollu, Veridix, part of Emmes Group
Key Takeaways
- Identify how AI tools can alleviate the workload of small discovery teams by automating preclinical documentation, reducing costs, and increasing the speed of IND submissions.
- Examine strategies for maintaining consistency across global regulatory filings by using AI to standardize reports from various CROs into uniform formats for different regional requirements.
Nageswara Kollu, Senior Director at Apellis Pharmaceuticals, explains how the discovery team leverages AI to automate preclinical documentation and regulatory filings, improving consistency and achieving significant time savings in the drug development process.
Faced with the challenge of managing complex workflows with a lean team, Apellis Pharmaceuticals is utilizing AI to standardize preclinical reports and streamline global IND submissions. This integration of technology reduces manual writing burdens and costs while ensuring the high level of quality and consistency necessary for diverse regulatory environments. By maintaining a "human-in-the-loop" approach, the discovery team can move beyond repetitive documentation to focus on critical data analysis and scientific decision-making.
Related to this article
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
In today’s ACT Brief, we examine why anti-kickback guidance and EHR-integrated trial matching must work together in community settings, why real-time trials depend on mature risk-based quality management, and how pharma is applying digital clones to predict outcomes.
The FDA’s RTCT initiative transmits predefined, clinically meaningful signals to regulators during active trials, so its value depends entirely on the maturity of sponsors’ upstream RBQM signal intelligence, KRIs, QTLs, and root-cause context, rather than on data speed.
In this video interview, Kent Thoelke, CEO of Paradigm Health, outlines why anti-kickback guidance and modern EHR-integrated trial matching technology must work in tandem to reach representative patient populations at the community level.
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
Real-Time Continuous Trials Through the Lens of Risk-Based Quality Management: Why RBQM Is the Infrastructure RTCT Cannot Exist Without
3
What Needs to Happen Beyond the Clinical Trial Modernization Act
4
Closing the Medical Writing Capacity Gap: Why Training Beats Technology
5